Long title
A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured anti-BCMA CAR T cells (BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (r/r MM) (Papilio-1)
Date receipt dossier
EudraCT number
2022-500782-27
Company / Sponsor
CellPoint B.V. (a Galapagos company)
Phase
I/II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Multiple Myeloma
Therapeutic approach
Immunotherapy
Genetic modification
BCMA CAR
Method of transfer of nucleic acid of interest
Lentiviral vector
Administered biological material
Autologous T cells transduced with lentiviral vectors expressing BCMA-CAR
Route of administration
Intravenous
Locations in Belgium
CHU de Liège, UZA, UZ Leuven, AZ Delta
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
BCMACP03, GLPG5301